Skipping part of radiation area in stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether delivering radiation to a smaller target area is as effective for certain inoperable stage III lung cancers, while potentially reducing side effects. It mainly looks for people who can safely receive a standard course of treatment and whose blood tests and health status fit the study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIA or IIIB non-small cell lung cancer that can’t be removed with surgery
- Your general health (ECOG) is 0 or 1, meaning you can function independently or with minor limits
- You’re expected to live more than 12 weeks, and you are between 18 and 80 years old
- Recent blood and organ test results are within required limits (white blood cells, platelets, liver, kidneys, and normal clotting)
- You are not pregnant or breastfeeding, and you can use reliable birth control during the study and for 8 weeks after treatment ends
- You must not have certain recent or past treatments and major health problems that could interfere with the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.